Cedar and cypress pollinosis and allergic rhinitis: quality of life effects of early intervention with leukotriene receptor antagonists.
BACKGROUND
Allergic rhinitis involves inflammation of the nasal passages. The use of nasal steroids is generally very effective in providing significant symptom relief. However, compliance for their use is sometimes poor.


METHODS
To examine the efficacy of early intervention (before pollen dispersal) with oral cysteinyl leukotriene receptor antagonists (LTRA) on pollinosis in patients with allergy to cedar and Japanese cypress pollens, groups of subjects were treated with LTRA or a placebo for 4 weeks at the beginning of the cedar pollen dispersal season. Subsequently, all patients received nasal steroid therapy concomitantly with LTRA throughout the remaining period of the pollen dispersal season. The effects of such early treatment with LTRA on pollinosis were investigated using symptom scores from an allergy diary and quality of life (QOL) scores.


RESULTS
Sneezing and nasal congestion scores were significantly lower in the LTRA-pretreated subjects than observed in the placebo-pretreated patients between weeks 4 and 6 and weeks 3 and 5, respectively. QOL scores improved significantly in all domains after concomitant therapy with nasal steroids. The percent improvement in the nasal congestion score after the concomitant therapy was significantly higher in the LTRA group (69%) than in the placebo group (41%).


CONCLUSIONS
Significant differences observed in symptoms and in QOL effects between LTRA- and placebo-pretreated patients and the absence of major adverse effects noted in these studies suggest that early intervention with LTRA is beneficial and safe and should be considered in the management of pollinosis-associated allergic rhinitis.
Sasaki
Keita
K
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Okamoto
Yoshitaka
Y
Yonekura
Syuji
S
Okawa
Toru
T
Horiguchi
Shigetoshi
S
Chazono
Hideaki
H
Hisamitsu
Minako
M
Sakurai
Daiju
D
Hanazawa
Toyoyuki
T
Okubo
Kimihiro
K
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002867:Chromones / Q000627:therapeutic use*; D032485:Cryptomeria / Q000276:immunology*; D029781:Cupressus / Q000276:immunology*; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011058:Pollen / Q000276:immunology; D011788:Quality of Life; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D011795:Surveys and Questionnaires
D002867:Chromones; D020024:Leukotriene Antagonists; C047681:pranlukast